LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

Search

Insulet Corp

Geschlossen

BrancheGesundheitswesen

145.05 1.14

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

141.4

Max

146.11

Schlüsselkennzahlen

By Trading Economics

Einkommen

-11M

91M

Verkäufe

-22M

762M

KGV

Branchendurchschnitt

34.612

49.712

EPS

1.3

Gewinnspanne

11.96

Angestellte

5,400

EBITDA

-23M

154M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+59.8% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.6B

10B

Vorheriger Eröffnungskurs

143.91

Vorheriger Schlusskurs

145.05

Nachrichtenstimmung

By Acuity

61%

39%

269 / 342 Ranking in Healthcare

Insulet Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Über Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat